Sirnaomics Ltd. (HK:2257) has released an update.
Sirnaomics Ltd. has issued a clarification on its previous announcement regarding the Phase I clinical study of its RNAi therapeutic, STP707, correcting the reported dosage levels and average days for stable disease in patients. The company stated that the dosages were in milligrams rather than milligrams per kilogram, and updated the stable disease duration for specific dosage groups. Apart from these corrections, all other details in the original announcement remain unchanged.
For further insights into HK:2257 stock, check out TipRanks’ Stock Analysis page.
